Tolulope T Sajobi, Olayinka I Arimoro, Ayoola Ademola, Nishita Singh, Fouzi Bala, Mohammed A Almekhlafi, Yan Deschaintre, Shelagh B Coutts, Sibi Thirunavukkarasu, Houman Khosravani, Ramana Appireddy, François Moreau, Gordon J Gubitz, Aleksander Tkach, Luciana Catanese, Dar Dowlatshahi, George Medvedev, Jennifer Mandzia, Aleksandra Pikula, Jai Shiva Shankar, Heather Williams, Thalia S Field, Alejandro Manosalva, Muzaffar Siddiqui, Atif Zafar, Oje Imoukhuede, Gary Hunter, Andrew M Demchuk, Sachin M Mishra, Laura C Gioia, Shirin Jalini, Caroline Cayer, Stephen J Phillips, Elsadig Elamin, Ashkan Shoamanesh, Suresh Subramaniam, Mahesh P Kate, Gregory Jacquin, Marie-Christine Camden, Faysal Benali, Ibrahim Alhabli, MacKenzie Horn, Grant Stotts, Michael D Hill, David J Gladstone, Alexandre Y Poppe, Arshia Sehgal, Qiao Zhang, Brendan Lethebe, Craig Doram, Michel Shamy, Carol Kenney, Brian H Buck, Richard H Swartz, Bijoy K Menon
BACKGROUND: Recent evidence from thrombolysis trials indicates the noninferiority of intravenous tenecteplase to intravenous alteplase with respect to good functional outcomes in patients with acute stroke. We examined whether the health-related quality of life (HRQOL) of patients with acute stroke differs by the type of thrombolysis treatment received. In addition, we examined the association between the modified Rankin Scale score 0 to 1 and HRQOL and patient-reported return to prebaseline stroke functioning at 90 days...
March 2024: Stroke; a Journal of Cerebral Circulation